Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duloxetine - Eli Lilly and Company

Drug Profile

Duloxetine - Eli Lilly and Company

Alternative Names: Ariclaim; Cymbalta; LY-227942; LY-248686; Xeristar; Yentreve

Latest Information Update: 09 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Shionogi
  • Class Antidepressants; Naphthalenes; Non-opioid analgesics; Propanolamines; Small molecules; Thiophenes
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Back pain; Depressive disorders; Diabetic neuropathies; Fibromyalgia; Generalised anxiety disorder; Major depressive disorder; Musculoskeletal pain; Neuropathic pain; Stress incontinence
  • Phase II/III Chronic fatigue syndrome

Most Recent Events

  • 12 Sep 2018 Efficacy and adverse events data from a phase III trial in Fibromyalgia presented at the 17th World Congress on Pain (WCP-2018)
  • 24 Jun 2018 Biomarkers information updated
  • 05 Feb 2018 Eli Lilly initiates enrolment in a phase III trial for Major depressive disorder in Japan (JapicCTI-183853)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top